Tanaka H, et al. - This study was planned to determine the efficacy and safety of nab-paclitaxel in patients with refractory advanced non-small cell lung cancer who failed previous chemotherapy. As per findings, single agent nab-paclitaxel had marked clinical efficacy and manageable toxicities for patients with chemorefractory advanced non-small cell lung cancer even in the third-line or later setting.